ZAMA MAJOLA
Uhlu lwezidakamizwa ezinciphisa isisindo kanye nesifo sikashukela lungasiza ekuguquleni umsuka wobhubhane lokukhuluphala ngokweqile, oluthinta abantu abangaphezu kwesigidigidi emhlabeni jikelele, kusho iWorld Health Organisation. Isizukulwane esisha sezidakamizwa ezicindezela ukudla ezibizwa ngokuthi ama-GLP-1 agonists okuhlanganisa nezinhlobo ze-blockbuster i-Ozempic ne-Mounjaro sesidume kakhulu eminyakeni yakamuva. Muva nje, inhlangano yezempilo yeZizwe Ezihlangene ikhiphe imihlahlandlela yayo yokuqala yokuthi izidakamizwa ezinjalo zingasetshenziswa kanjani njengethuluzi elibalulekile lokwelapha ukukhuluphala kubantu abadala njengesifo esingalapheki, esibuyela emuva.
Bangaphezu kwezigidi ezingu-3.7 abantu ababulawa yizifo ezihlobene nokukhuluphala ngokweqile ngo-2022, ngokwezibalo ze-WHO — ngaphezu kwezifo ezithathelwanayo eziphezulu umalaleveva, isifo sofuba kanye ne-HIV kuhlangene. Isibalo sabantu abaphila nokukhuluphala ngokweqile sizophindeka kabili ngo-2030 ngaphandle uma kuthathwa izinyathelo ezinqala zokunqanda lokhu kukhula. “Ukukhuluphala kuyinselelo enkulu yezempilo emhlabeni wonke,” kusho isikhulu se-WHO uTedros Adhanom Ghebreyesus esitatimendeni. “Yize imithi yodwa ingeke iyixazulule lenkinga yezempilo yomhlaba wonke, izindlela zokwelapha ze-GLP-1 zingasiza izigidi ukuba zinqobe ukukhuluphala futhi zinciphise ukulimala okuhambisana nakho. Imihlahlandlela emisha ifuna ukuthi izindlela zokwelapha ze-GLP-1 zisetshenziswe abantu abadala, ngaphandle kwabesifazane abakhulelwe, “ekwelapheni isikhathi eside sokukhuluphala”. I-WHO yengeza i-GLP-1s ohlwini lwayo lwemithi ebalulekile.
